Welcome to our dedicated page for Delcath Sys news (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Sys stock.
The Delcath Systems Inc (DCTH) news page on Stock Titan aggregates company announcements, clinical updates, and financial disclosures for this interventional oncology business focused on primary and metastatic liver cancers. Delcath’s communications frequently highlight developments related to its proprietary hepatic delivery technologies, HEPZATO KIT and the CHEMOSAT Hepatic Delivery System for Melphalan, which are used in percutaneous hepatic perfusion (PHP) procedures.
Investors and observers can use this news feed to follow earnings reports and financial updates, including quarterly and preliminary revenue results, product revenue from HEPZATO KIT in the United States and CHEMOSAT in Europe, gross margin commentary, and discussions of non-GAAP measures such as adjusted EBITDA. The company also issues releases on capital allocation and corporate actions, such as authorization of share repurchase programs and equity inducement grants under stock incentive plans.
A significant portion of Delcath’s news flow centers on clinical and scientific developments. Recent announcements describe subgroup analyses from the Phase 3 FOCUS study of Melphalan/Hepatic Delivery System in unresectable metastatic uveal melanoma, the Phase 2 CHOPIN trial evaluating CHEMOSAT with ipilimumab and nivolumab, real-world evidence from retrospective analyses of metastatic uveal melanoma patients, and a 10-year single-center experience with CHEMOSAT in liver-dominant disease. The company also highlights expert narrative reviews discussing PHP with melphalan using HEPZATO KIT, including patient selection, technique, and outcomes.
Additional updates include participation in investor conferences and scheduling of earnings calls, providing context for how Delcath communicates with the capital markets. For users tracking DCTH, this page offers a centralized view of regulatory, clinical, and financial news that shapes the company’s progress in liver-directed oncology therapies. Bookmark this feed to monitor new data releases, product-related publications, and ongoing disclosures from Delcath Systems Inc.
Delcath Systems, Inc. (DCTH), a leader in interventional oncology, will present at three key healthcare conferences in September 2021. The H.C. Wainwright 23rd Annual Global Investment Conference runs from September 13-15, featuring on-demand presentations starting September 13 at 7:00 AM (ET). Next is the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20-23, with a presentation on September 21 at 12:25 PM (ET). Lastly, the Cantor Fitzgerald Healthcare Conference will occur September 27-30, with a presentation on September 29 at 4:40 PM (ET).
Delcath Systems, Inc. (DCTH) reported its Q2 2021 financial results, showing product revenue of approximately $536K, up from $379K year-over-year. Despite this growth, the company incurred a net loss of $6.4M compared to a net income of $4.3M in Q2 2020. Key highlights include positive results from the FOCUS Phase III trial of HEPZATO™ KIT, with a 29.2% overall response rate in treated patients. Additionally, Delcath's CHEMOSAT® received updated guidance from the UK's National Institute for Health and Care Excellence, enhancing treatment funding prospects.
Delcath Systems (DCTH) has secured a debt facility of up to $20 million from Avenue Venture Fund, with an initial $15 million funded at closing. This financing aims to support the upcoming NDA filing for HEPZATO™, targeting the treatment of hepatic-dominant metastatic ocular melanoma, anticipated in early 2022. CEO Gerard Michel expressed optimism regarding the partnership, which will aid in advancing Delcath's innovative cancer treatment approaches.
Delcath Systems, Inc. (Nasdaq: DCTH) announced its participation in two key conferences. The BTIG Virtual Biotechnology Conference is set for August 9, 2021, from 10:00-10:25 AM ET, featuring management-led 1x1 investor meetings. The Canaccord Genuity 41st Annual Growth Conference will follow on August 11, 2021, at 10:00 AM ET, with a webcast available at this link. Delcath specializes in treating liver cancers through its proprietary PHP system.
Delcath Systems, Inc. (Nasdaq: DCTH) will host a conference call on August 10, 2021, at 8:30 AM ET to discuss its second-quarter results for the period ending June 30, 2021. The call will be accessible via phone and online. Delcath focuses on providing innovative treatments for rare liver cancers through its proprietary PHP system, which allows high-dose chemotherapy directly to the liver, minimizing systemic side effects. In Europe, the PHP system is marketed as CHEMOSAT, while in the U.S., it is under the name HEPZATO KIT.
Delcath Systems, focused on interventional oncology for liver cancers, will present at the Access to Giving Virtual Conference on July 13, 2021, at 3 p.m. ET. CEO Gerard Michel will lead the discussion. This conference allows companies to engage with investors while supporting charitable causes. Registration is free and can be done online. Delcath’s investigational product, HEPZATO KIT, aims to deliver high-dose chemotherapy to the liver, although it is not approved by the FDA in the U.S. The system is marketed in Europe as Delcath CHEMOSAT.
Delcath Systems is set to join the Russell Microcap® Index on June 28, 2021, following the annual reconstitution. This membership will remain for one year and includes automatic inclusion in growth and value style indexes. The CEO, Gerard Michel, emphasized that this milestone enhances the company's visibility among investors. Russell indexes manage approximately $10.6 trillion in assets, being widely used by institutional investors for benchmarking. Delcath focuses on treating liver cancers using its proprietary PHP system, marketed as HEPZATO in the US and CHEMOSAT in Europe.
Delcath Systems (DCTH) reported positive preliminary results from its FOCUS Phase III trial for HEPZATO in treating liver-dominant metastatic ocular melanoma. The study achieved a significant overall response rate of 29.2%, exceeding the prespecified 8.3% threshold. Notably, 44% of patients treated with HEPZATO demonstrated a 30% or greater reduction in tumor size, compared to only 17% in the Best Alternative Care arm. The company will hold a Q&A webinar to discuss these findings further.
Delcath Systems, focused on interventional oncology, announced its management will present at the LD Micro Virtual Investor Conference on June 10, 2021, at 2:30 p.m. ET. This event will feature a live audio webcast accessible through their official link. Delcath’s investigational product, HEPZATO KIT, aims to treat primary and metastatic liver cancers by delivering high-dose chemotherapy while minimizing systemic exposure. Although not FDA-approved in the U.S., it is marketed in Europe under the CHEMOSAT name and has been CE Marked for use.
Delcath Systems (DCTH) announced management will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 4:00 PM (ET). The event provides a platform for showcasing Delcath's focus on treating rare primary and metastatic liver cancers using their investigational product, HEPZATO KIT, designed for high-dose chemotherapy delivery to the liver. While the HEPZATO KIT is not yet FDA-approved, it is marketed in Europe as CHEMOSAT, used in major medical centers. For more details, visit their conference page linked in the announcement.